New drug combo may boost stem cell transplants for blood cancers
NCT ID NCT04395222
First seen Jan 08, 2026 · Last updated May 14, 2026 · Updated 16 times
Summary
This study tests whether replacing a standard immune-suppressing drug with tocilizumab can improve stem cell transplant success in 21 adults with blood cancers. The goal is to prevent graft failure and graft-versus-host disease while reducing cancer relapse. Participants receive a haplo-cord transplant, combining cells from a half-matched donor and umbilical cord blood.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEMATOLOGIC MALIGNANCY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Weill Cornell Medical College
New York, New York, 10065, United States
Conditions
Explore the condition pages connected to this study.